Comparison of procalcitonin (PCT) and C-reactive protein (CRP) plasma concentrations at different SOFA scores during the course of sepsis and MODS
Michael Meisner, Klaus Tschaikowsky, Thomas Palmaers and Joachim Schmidt

Objectives: The relation of procalcitonin (PCT) plasma concentrations compared with C-reactive protein (CRP) was analyzed in patients with different severity of multiple organ dysfunction syndrome (MODS) and systemic inflammation.

Patients and methods: PCT, CRP, the sepsis-related organ failure assessment (SOFA) score, the Acute Physiology, Age, Chronic Health Evaluation (APACHE) II score and survival were evaluated in 40 patients with systemic inflammation and consecutive MODS over a period of 15 days.

Results: Higher SOFA score levels were associated with significantly higher PCT plasma concentrations (SOFA 7–12: PCT 2.62 ng/ml, SOFA 19–24: PCT 15.22 ng/ml) (median), whereas CRP was elevated irrespective of the scores observed (SOFT 7–12: CRP 131 mg/l, SOFT 19–24: CRP 135 mg/l). PCT of non-surviving patients was initially not different from that of survivors but significantly increased after the fourth day following onset of the disease, whereas CRP was not different between both groups throughout the whole observation period.

Conclusions: Measurement of PCT concentrations during multiple organ dysfunction syndrome provides more information about the severity and the course of the disease than that of CRP. Regarding the strong association of PCT and the respective score systems in future studies we recommend evaluation also of the severity of inflammation and MODS when PCT concentrations were compared between different types of disease.

Introduction
Procalcitonin (PCT) is a precursor protein of the hormone calcitonin with a molecular weight of approximately 13kDa. PCT is induced in the plasma of patients with severe bacterial or fungal infections or sepsis [1,2]. PCT concentrations up to 1000 ng/ml and above are observed during severe sepsis and septic shock [2–5]. Local bacterial infections, viral infections, autoimmune and allergic disorders do not induce PCT. At present, it is not clear whether PCT is predominantly influenced merely by inflammation induced by microbial infections, or also by the severity of multiple organ dysfunction secondary to the systemic inflammatory response. Recent investigations have mainly focused on sepsis-related severity scores, eg the American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference (ACCP/SCCM) criteria [6–8] or related scores [9,10], but have not yet examined the relation of PCT concentrations to multiorgan dysfunction independent from the etiology of sepsis. However, in severely ill patients presenting with symptoms of systemic inflammation or septic shock, the presence or absence of a significant infection cannot always be specified, eg positive bacterial cultures can be isolated with increasing quantity in patients with increasing severity of disease [11]. We thus investigated the relation between PCT concentrations and the severity of organ dysfunction assessed by the sepsis-related organ failure assessment (SOFA) score in patients with multiple organ dysfunction syndrome (MODS) secondary to systemic inflammation of infectious or non-infectious origin. The SOFA score is a multiorgan dysfunction score system and estimates organ dysfunction (Table 1) [12]. We also measured the Acute Physiology, Age, Chronic Health Evaluation (APACHE) II score [13] and compared PCT with the widely known marker of the inflammatory response, the acute phase C-reactive protein (CRP). Since PCT is also reported as an interesting parameter to estimate the prognosis of sepsis and severe systemic inflammatory response [4,10,14–19], we also compared the course of concentrations in patients when classified as survivors and non-survivors.
Methods

Forty patients of an anaesthesia and surgery intensive care unit in a tertiary health care institution were prospectively included into the study when systemic inflammatory response syndrome (SIRS) or sepsis criteria according to the ACCP/SCCM definitions [7] were fulfilled for a period of no longer than 24 h. Patients with SIRS or sepsis were not separately analysed, since distinction between infectious and non-infectious etiology of systemic inflammation and MODS is often difficult in severely ill patients, and this was not an objective of our study. PCT and CRP plasma concentrations, the SOFA score [12] and the APACHE II score [13] were determined daily on observation day 1 to 5, and on days 8 and 15 after onset of symptoms of SIRS or sepsis. Patients were followed-up for 28 days and were then assigned to the group of survivors and non-survivors, respectively. Sixteen patients survived and 14 patients had a lethal outcome in the further course of the disease within the 28-day observation period. PCT was measured by an immunoluminometric ‘LUMItest®PCT’-kit (B.R.A.H.M.S. – Diagnostica GmbH, Berlin, Germany) and CRP by the ‘Turbi-Quanti’ method (Behring, Marburg, Germany).

Statistics

The correlations between the SOFA score and CRP and PCT concentrations were calculated. Since PCT concentrations were not normally distributed, PCT data were analyzed using four categories of the SOFA to which patients were assigned, and the median and 25/75 and 10/90 percentiles were determined. Differences of median PCT levels between these SOFA groups were analyzed by the Mann–Whitney U test. By definition of four categories, data were comparable with other semi-quantitative scoring systems of the septic response, eg the previously published relation to ACCP/SCCM criteria [4,5]. Significance was assumed when \( P < 0.05 \).

Results

Forty patients with SIRS or sepsis were included in the study and finally evaluated on a total of 316 observation days. Fourteen patients died from their underlying disease during the observation period of 28 days. The data at the time of enrolment (observation day 1) are shown both for survivors and non-survivors (Table 2).

SOFA score: comparison with PCT and CRP

For all patients observed, PCT and CRP concentrations within the four groups of increasing categories of the SOFA score are shown in Figs 1 and 2. Median of PCT concentrations significantly increased with increasing SOFA score levels of the patients (Fig 1). In contrast, CRP concentrations were found highly elevated also at low SOFA scores and showed no significant difference between these groups (Fig 2). Only a few measurements detected very high PCT levels, whereas the majority of the PCT concentrations are in the intermediate range. Thus, correlation coefficients between PCT levels and SOFA scores were low (\( r = 0.20 \)). Likewise, there was only a weak correlation between SOFA scores and CRP levels (\( r = 0.19 \)). Similar data were obtained for the APACHE II score (\( r = 0.17 \) and \( r = 0.07 \), respectively; Table 3).

### Table 1

The sepsis-related organ failure assessment (SOFA) score evaluation system of multiple organ dysfunction [12]. Six organ systems are evaluated as a scale of 1–4 each. The arithmetical sum of these six is the value of the SOFA score.

| Score points | 1 | 2 | 3 | 4 |
|-------------|---|---|---|---|
| Respiration | PaO₂/FiO₂ | <400 | <300 | <200 | <100 |
| Coagulation | Platelets x10⁹/mm³ | <150 | <100 | <50 | <25 |
| Liver | Bilirubin mg/dl | 1.2–1.9 | 2.0–5.9 | 6.0–11.9 | >12.0 |
| Cardiovascular | Hypotension\( ^a \) | MAP <70 mmHg | Dopamine ≤5 or dobutamine in any dose | Dopamine >5 or epinephrine ≤0.1 or norepinephrine ≤0.1 | Dopamine >15 or epinephrine >0.1 or norepinephrine >0.1 |
| Central nervous system | Glasgow Coma Scale | 13–14 | 10–12 | 6–9 | <6 |
| Renal | Creatinine mg/dl or urine output | 1.2–1.9 | 2.0–3.4 | 3.5–4.9 or <500 ml/24 h | 5.0 or <200 ml/24 h |

\( ^a \)Adrenergic agents administered for at least 1 h (doses are given in \( \mu \)g/kg/min). MAP, mean arterial pressure.
The course of PCT and CRP: relation to the outcome

During the first 4 days after the onset of systemic inflammation and MODS, PCT concentrations of patients who survived were not significantly different from those who died (Fig 3). In both groups, median PCT concentrations initially declined, indicating a decrease of the initially observed systemic inflammation during the further course of the disease. This decline continued in the group of patients who survived, whereas PCT concentrations started to increase in the non-survivors after observation day 4 \( (P < 0.01) \). CRP levels were marginally higher in patients who survived than in non-survivors. However, plasma concentrations were not significantly different between survivors and non-survivors on all observation days except day 2 \( (197 \text{ versus } 129 \text{ mg/l, } P < 0.01) \) (Fig 4).

Discussion

Our results indicate that PCT concentrations are associated with the severity of MODS as assessed by the SOFA score. These results are in general agreement with studies in which PCT levels were compared with the severity of sepsis by sepsis-related score systems. The similar observations made by sepsis-related score systems of the inflammatory response and MODS-
weighted score systems can be explained by similar pathophysiological alterations occurring during advanced states of sepsis and MODS. Increasing PCT concentrations were previously reported by Zeni et al [5] and Oberhofer et al [4] during more severe stages of sepsis (severe sepsis and septic shock) as defined by the ACCP/SCCM criteria [7,20]. Also, other authors observed high concentrations of PCT during septic shock, and comparable low concentrations during SIRS or less severe systemic inflammation. In a study by Al-Nawas et al [6], very low PCT concentrations were measured during SIRS, but high concentrations when septic shock was diagnosed. Similar results were published by Gramm et al [10] and by other authors [1,9].

None of these authors, however, analyzed the severity of multiple organ dysfunction rather than the severity of sepsis and systemic inflammation and there are no data available as to the relation of PCT concentrations and score values is weak.

These findings have an impact on the interpretation and design of comparative clinical studies using PCT. When PCT levels are to be compared between different groups of patients, for purposes of differential diagnosis, assessment of the severity of the disease and of systemic inflammation, including the severity of MODS, is mandatory. When patients were not stratified clearly enough for severity of MODS and systemic inflammation in clinical studies, imbalances between groups as to the severity of MODS or sepsis may significantly influence the significance of different PCT concentrations between the respective groups. We therefore suggest that in future studies score systems evaluating not only the severity of systemic inflammation, but also of MODS should be assessed along with PCT concentrations. This way, imbalances between groups as to severity of inflammation or MODS can be minimized.

PCT has several advantages in severely ill patients compared with CRP. The most striking one, demonstrated in this study, is the enormous range of PCT reactivity resulting in a marked increase in PCT plasma levels, especially during severe stages of MODS and systemic inflammation. On the other hand, PCT concentrations are quite low when only a moderate organ dysfunction or a weak systemic inflammatory response is present. In contrast, CRP levels are often found to be already increased to maximal

---

**Figure 3**

Course of procalcitonin (PCT) plasma concentrations in 40 patients during 15 days after onset of sepsis or multiple organ dysfunction syndrome (MODS). Indicated are median and 25/75 percentiles (whiskers) of PCT concentrations of 14 patients with a lethal outcome (●, solid line) during a 28-day observation period due to the underlying disease, and of 26 patients who survived (○, dashed line).

**Figure 4**

The course of C-reactive protein (CRP) plasma concentrations in 40 patients during 15 days after onset of sepsis or multiple organ dysfunction syndrome (MODS). Indicated are median and 25/75 percentiles (whiskers) of CRP concentrations of 14 patients with a lethal outcome (●, solid line) during a 28-day observation period due to the underlying disease, and of 26 patients who survived (○, dashed line).
concentrations in patients with low SOFA scores. Thus, CRP cannot provide information as to further increases in organ dysfunction and the inflammatory progress, respectively, since it is already increased to its maximum values during a less severe stage of disease. Further advantages of PCT are its more rapid kinetics; PCT reacts faster than CRP both during an increase or decrease of inflammation. Although data were not presented, a more rapid increase of PCT was observed also in this study [17]. This observation was already described by several authors and thus is not focused on within this study, eg after experimental administration of lipopolysaccharide [21] or accidental application of a microbial contaminated infusion [22], where PCT increased within 6 h after the initial stimulus and CRP did not significantly increase before 12 h after onset of induction. Also, under clinical conditions, a more rapid increase of PCT compared with CPR was described after the onset of severe inflammation [23]. Moreover, the decline of PCT concentrations occurs more rapidly than that of CRP [2,23]. In this study, a rapid decline of PCT levels in patients who recovered and survived was also observed (Fig 3), whereas CRP increased for several days even after recovery and discharge of the patient from the intensive care unit (Fig 4).

Regarding the prognosis of the disease, the course of PCT after day 4 from the onset of systemic inflammation was able to distinguish survivors from non-survivors. Until day 4, PCT concentrations were not statistically different in the groups. Likewise, the initial height of the PCT concentrations did not correlate with the further course of the disease. The results of this analysis should not be over-interpreted. The number of patients is too small and too heterogeneous for a general conclusion regarding the absolute height of PCT concentrations and estimating the prognosis of the disease by PCT. In a clinical study, Oberhoffer et al report high PCT levels in patients with poor prognosis already during the onset of the disease [4]. Further studies support the notion that the course of PCT concentrations rather than the absolute height is a mirror of the systemic inflammatory response and plays a major role for prognosis [4,10,18,19]. Also with regard to this aspect, PCT is superior to CRP, since patients with a lethal outcome were not distinguished by CRP at any time in our study. A recently conducted animal study by Nylen et al [24] suggests that PCT might be a significant lethal factor during sepsis. In this experimental study, PCT significantly increased mortality in a hamster endotoxin shock model, and anti-PCT reactive antisera was protective as to survival.

In summary, PCT compared with CRP is characterized by its ability to be induced to very high serum concentrations also during advanced stages of MODS and severe systemic inflammation, respectively, whereas CRP is often already in the upper concentration range, even in patients with low severity scores, and exhibits no such further dynamics during the course of MODS and systemic inflammation. PCT more rapidly declines to the normal range during the recovery of the patient compared with CRP, and thus provides more information in patients with MODS and sepsis of various etiology than CRP. The absolute height of PCT concentrations in the initial period of inflammation was found to be less important than the further course of its plasma concentrations. The strong association of high PCT concentrations with both the SOFA and the APACHE II score indicates that not only sepsis-related score systems, but also a MODS-related evaluation of the severity of the diseases should be considered when PCT concentrations of different types of disease were compared.

References
1. Assicot M, Gendrel D, Carsin H, et al: High serum procalcitonin concentrations in patients with sepsis and infection. Lancet 1993; 341:515–518.
2. Meisner M: PCT, procalcitonin — a new, innovative infection parameter. Berlin: B R A H M S-Diagnostica GmbH; 1996.
3. Meisner M, Tschakoway K, Beier W, et al: Procalcitonin (PCT) — ein neuer Parameter zur Diagnose und Verlaufskontrolle von bakteriellen Entzündungen und Sepsis. Anästhesiologie und Intensivmedizin 1996; 10:529–539.
4. Oberhoffer M, Mögel D, Mai-Heismann A, et al: Procalciton in is higher in non-survivors during the clinical course of sepsis, severe sepsis and septic shock. Intensive Care Med 1996; 22:A245.
5. Zeni F, Villain A, Assicot M, et al: Procalcitonin serum concentrations and severity of sepsis. Clin Intens Care 1994; 5 (suppl 2):90–96.
6. Al-Nawas B, Kramer M, Shah PM: Procalcitonin in diagnosis of severe infections. Eur J Med Res 1996; 1:331–333.
7. Anonymous: American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992; 20:864–874.
8. Oberhoffer M, Bitterlich A, Hentschel T, et al: Procalcitonin (ProCT) correlates better with the ACCP/SCCM consensus conference definitions than other specific markers of the inflammatory response. Clin Intens Care 1996; 7 (suppl 1):48.
9. de Werra I, Jaccard C, Corradin SB, et al: Cytokines, nitrite/nitrate, soluble tumor necrosis factor receptors, and procalcitonin concentrations: comparisons in patients with septic shock, cardiogenic shock, and bacterial pneumonia. Crit Care Med 1997; 25:607–613.
10. Grimm HJ, Dollinger P, Beier W: Procalcitonin — ein neuer Marker der inflammatorischen wirtsantwort. Longitudinalstudien bei Patienten mit sepsis und Peritonitis. Chir Gastroenterol 1995; 11 (suppl 2):51–54.
11. Rangel-Frausto MS, Pittet D, Costigan M, et al: The natural history of the systemic inflammatory response syndrome (SIRS). JAMA 1995; 273:117–123.
12. Vincent JL, Moreno R, Takala J, et al: The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. Intensive Care Med 1996; 22:707–710.
13. Knaus WA, Draper E, Wagner E, et al: APACHE II: a severity of disease classification system. Crit Care Med 1985; 13:818–829.
14. Gramm HJ, Beier W, Zimmermann J, et al: Procalcitonin (ProCT) — a biological marker of the inflammatory response with prognostic properties. Clin Intens Care 1995; 6 (suppl 2):71.
15. Meisner M, Tschakoway K, Palmarens T, et al: Prognostische Bedeutung von Procalcitonin (PCT) bei Patienten mit Sepsis und systemischer Inflammation. Anaesthesiol Intensivmed Notfallmed Schmerzther 1997; 32:177.
16. Meisner M, Tschakoway K, Spiesal C, et al: Procalcitonin — a marker or modulator of the acute immune response? Intensive Care Med 1996; 22 (suppl 1):14.
17. Palmarens T: Procalcitonin bei Sepsis und Ganzkörperfieber: Prognostische Aussagekraft und ein Vergleich mit C-reactivem Protein. Germany: University of Erlangen; 1998.
18. Reith HB, Lehmkuhl P, Beier W, et al: Procalcitonin – ein prognostischer Infektionsparameter bei der Peritonitis. Chir Gastroenterol 1995; 11 (suppl 2):47–50.

19. Reith HB, Mittelkötter U, Debus ES, et al: Procalcitonin (PCT) immunoreactivity in critical ill patients on a surgical ICU. In: Mondruzi (editor). The Immune Consequences of Trauma, Shock and Sepsis. Bologna 1997; 1:673–677.

20. Bone RC: Definitions for sepsis and organ failure. Crit Care Med 1992; 19:973–976.

21. Dandona P, Nix D, Wilson MF, et al: Procalcitonin increase after endotoxin injection in normal subjects. J Clin Endocrinol Metab 1994; 79:1605–1608.

22. Brunkhorst FM, Forczyk ZF, Wagner J: Release and kinetics of procalcitonin (PCT) after Gram-negative bacterial injection in a healthy subject. Shock 1997; 7:124.

23. Monneret G, Labaune JM, Isaac C, et al: Procalcitonin and C-reactive protein levels in neonatal infections. Acta Paediatr 1997; 86:209–212.

24. Nylen ES, Whang KT, Snider RH, et al: Mortality is increased by procalcitonin and decreased by an antiserum reactive to procalcitonin in experimental sepsis. Crit Care Med 1998; 26:1001–1006.